The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of AEs
Timeframe: 0-113 Days for SAD; 0-143 Days for MAD
Incidence of laboratory abnormalities
Timeframe: 0-113 Days for SAD; 0-143 days for MAD
Incidence of ECG abnormalities
Timeframe: 0-113 Days for SAD; 0-143 Days for MAD
Incidence of vital sign abnormalities
Timeframe: 0-113 Days for SAD; 0-143 Days for MAD